Firms

Life Sciences at Goldman Sachs Alternatives

Life Sciences at Goldman Sachs Alternatives

am.gs.com

Life Sciences at Goldman Sachs Alternatives is the specialist life sciences investing group within Goldman Sachs Asset Management’s alternatives platform. Established in 2021 and led by Amit Sinha, it invests in private therapeutics companies entering clinical development or in early clinical stages, including neuroscience, precision and genetic medicine, cell therapies, immunotherapy and technologies such as synthetic biology and AI. Its first fund, West Street Life Sciences I, closed in January 2024 with USD650 million in equity commitments. The current strategy page reports more than USD1 billion in aggregate capital raised as of June 2026 and 21 investments as of July 2026; 19 are disclosed and two preclinical companies remain in stealth. These aggregate figures are distinct from the first fund’s size. Verified neuroscience investment Newleos Therapeutics includes the strategy as Series A lead in February 2025. This profile represents the specialist investment team, not a separate corporate entity or all Goldman Sachs businesses.

Founded
—
Type
Venture capital

Funds1

  • West Street Life Sciences I$650M

    First fund of Goldman Sachs Asset Management’s life sciences investing strategy, announced at final close with USD650 million in equity commitments. Targets early and middle clinical development, therapeutics, tools and diagnostics; reported aggregate strategy capital raised subsequently exceeds USD1 billion and is not this fund’s size.

Team

Operations and support

Adriana TajonarAdriana TajonarManaging Director
Amit SinhaAmit SinhaGlobal Head and Chief Investment Officer, Life Sciences Investing
Ania M. JastreboffAnia M. JastreboffAdvisory Board Member
Colin WalshColin WalshManaging Director
David ChangDavid ChangAdvisory Board Member
Diane MathisDiane MathisAdvisory Board Member
Josh RichardsonJosh RichardsonManaging Director
Lloyd MinorLloyd MinorAdvisory Board Member
Ming CheahMing CheahVice President, Life Sciences Investing
Ryan WattsRyan WattsCEO, Denali Therapeutics
Sean NolanSean NolanAdvisory Board Member

Co-investing

Investments